Ovarian Cancer

An overview of factors that influence the initiation of maintenance therapy for patients with ovarian cancer.

Chad A. Hamilton, MD, discusses how clinical trial data inform treatment selection for patients with ovarian cancer.

A comprehensive overview of the maintenance therapy landscape in ovarian cancer, with a focus on clinical trials investigating bevacizumab, olaparib, and niraparib.

An expert gynecologic oncologist reviews guideline recommendations for molecular testing in ovarian cancer and shares his testing practices.

Chad A. Hamilton, MD, presents the case of a 49-year-old woman with BRCA wild-type ovarian cancer and offers his initial impressions.

Barbara Buttin, MD, provided insight on the phase 3 DUO-O trial and what it implies for the future of ovarian cancer treatment.

In an interview with Targeted Oncology, Barbara Buttin, MD, discussed important ovarian cancer research for which results were presented during the 2023 ASCO Annual Meeting.

There was no difference in the risk of disease progression or death outcomes noted between patients with ovarian cancer treated with batiraxcept and paclitaxel vs batiraxcept alone in the AXLerate-OC trial.

Topline results reported from the UPLIFT trial showed it did not meet its primary end point of objective response rate in the NaPi2b-positive population with ovarian cancer.

During a Targeted Oncology™ Clinical Case Forum™ event, Lyndsay Willmott, MD, discussed the data supporting the use of PARP inhibitors as primary maintenance therapy for patients with ovarian cancer.

Niraparib as a monotherapy is supported as standard of care for a broad patient population with advanced ovarian cancer after first-line platinum-based chemotherapy.

Christina Fotopoulou, MD, PhD, discusses the results of the DUO-O trial in patients with newly diagnosed ovarian cancer.

Leslie Randall, MD, MAS, offers closing thoughts on the future trajectory of ovarian cancer treatment.

An expert gynecologic oncologist comments on recent revisions to FDA-approved indications for PARP inhibitors in the treatment of ovarian cancer.

Leslie Randall, MD, MAS, reviews recent long-term data on PARP inhibitors in the treatment of ovarian cancer.

Clinical insights on how to manage adverse events for patients with ovarian cancer who are receiving PARP inhibitors.

An expert on ovarian cancer discusses factors that influence PARP inhibitor selection, when to initiate maintenance therapy, and how to counsel patients on PARP inhibitors.

Leslie Randall, MD, MAS, reviews the available treatment options for BRCA-mutated advanced ovarian cancer.

An overview of guideline recommendations for molecular testing in ovarian cancer.

Leslie Randall, MD, MAS, presents the case of a 55-year-old woman with BRCA-mutated ovarian cancer and provides her initial impressions.

The combination of avutometinib with defactinib elicited high activity in patients with recurrent low-grade serous ovarian cancer, according to data from RAMP 201.

The use of maintenance niraparib therapy led to clinically meaningful improvement in progression-free survival, compared with placebo, in patients with newly diagnosed, advanced ovarian cancer.

Second-line maintenance therapy with niraparib improved overall survival in a BRCA gene wild-type population with recurrent ovarian cancer.

Kathleen N. Moore, MD says the phase 3 MIRASOL results bring a new standard-of-care to the FRα-high, platinum-resistant ovarian cancer landscape.

Phase 3 DUO-O study results reveal a promising strategy for patients with HRD-negative advanced ovarian cancer.